acut
diarrhea
common
often
selflimit
caus
present
veterinari
care
yet
pauciti
data
frequentlyprescrib
treatment
purpos
random
doubl
blind
placebocontrol
clinic
trial
compar
two
anecdotallyrecommend
treatment
probiot
combin
metronidazol
sixti
dog
without
concurr
comorbid
random
three
treatment
group
time
resolut
diarrheal
sign
evalu
use
owner
survey
fecal
score
chart
dog
present
acut
diarrhea
achiev
accept
fecal
consist
day
receiv
probiot
day
oral
metronidazol
day
placebo
statist
signific
differ
identifi
treatment
group
p
find
fail
provid
evid
common
use
metronidazol
cohort
dog
acut
canin
diarrhea
larger
studi
popul
would
requir
identifi
statist
signific
effect
probiot
much
treatment
acut
canin
diarrhea
remain
empir
confound
selflimit
natur
condit
helminth
protozo
infect
primari
bacteri
viral
enter
may
caus
acut
diarrhea
dog
major
case
caus
inappar
rel
risk
diarrhea
may
influenc
strongli
age
breed
gender
environ
season
dietari
indiscret
hous
stress
kennel
shelter
environ
also
predispos
factor
acut
diarrhea
potenti
resolut
may
affect
either
primari
secondari
chang
fecal
microbiota
area
present
receiv
substanti
research
interest
antimicrobi
drug
probiot
administ
frequent
treatment
acut
diarrhea
goal
influenc
gastrointestin
microbiom
shorten
time
clinic
resolut
probiot
may
repres
viabl
altern
treatment
strategi
antibiot
administr
given
concern
antimicrobi
efficaci
resist
acut
diarrhea
probiot
classic
defin
live
viabl
microorgan
produc
evid
health
benefit
administ
variabl
effect
dog
observ
strain
follow
bacteri
genera
lactobacillu
enterococcu
bacillu
streptococcu
bifidobacterium
pediococcu
weissella
clinic
studi
evalu
impact
probiot
suggest
possibl
prophylact
effect
diarrhea
result
intens
exercis
shelter
environ
recent
placebocontrol
studi
conclud
probiot
may
reduc
durat
clinic
sign
dog
administ
combin
probiot
treatment
acut
diarrhea
multipl
caus
similar
studi
improv
fecal
qualiti
follow
administr
probiot
ferment
milk
product
report
howev
probiot
effect
like
conditionand
strainspecif
metronidazol
nitroimidazol
antibiot
empir
prescrib
treatment
acut
chronic
canin
diarrheal
diseas
mechan
action
antibacteri
antiprotozo
effect
remain
incomplet
understood
believ
inhibit
bacteri
dna
induc
oxid
damag
primarili
anaerob
bacteria
drug
effect
giardia
clostridium
spp
make
theoret
attract
choic
suggest
caus
diarrheal
pathogen
metronidazol
may
also
immunomodulatori
antiinflammatori
effect
differ
detect
dog
inflammatori
bowel
diseas
given
prednison
metronidazol
vs
prednison
alon
administr
healthi
dog
caus
signific
chang
microbiom
persist
follow
discontinu
drug
unknown
clinic
effect
singl
prospect
random
blind
trial
dog
acut
hemorrhag
diarrhea
fail
demonstr
benefici
effect
metronidazol
administr
addit
amoxicillinclavulan
acid
support
therapi
use
metronidazol
acut
nonhemorrhag
canin
diarrhea
subject
placebocontrol
trial
purpos
studi
evalu
combin
probiot
greater
number
strain
higher
number
coloni
form
unit
cfu
use
similar
studi
resolut
acut
uncompl
diarrhea
dog
compar
altern
treatment
metronidazol
placebo
clientown
dog
present
either
two
emerg
center
univers
veterinari
academ
teach
hospit
recruit
enrol
random
doubleblind
placebocontrol
clinic
trial
march
august
elig
criteria
evalu
attend
clinician
includ
acut
sign
day
diarrhea
without
concurr
vomit
bodi
weight
kg
lack
clinicallyrelev
comorbid
would
expect
caus
secondari
diarrhea
endocrinopathi
organ
dysfunct
immunemedi
diseas
suspect
pancreat
base
sever
abdomin
pain
etc
dog
clinic
sign
consist
sever
acut
hemorrhag
diarrhea
syndrom
character
signific
dehydr
hypovolemia
subject
larg
volum
hematochezia
exclud
elig
discret
attend
clinician
time
present
owner
inform
studi
design
consent
particip
studi
approv
hospit
research
review
committe
institut
anim
care
use
committe
iacuc
client
provid
financi
incent
particip
agre
answer
survey
present
particip
phone
interview
day
initi
treatment
owner
provid
fecal
score
chart
ask
observ
defec
event
record
day
fece
first
consist
score
less
provid
chart
repres
fece
form
owner
ask
record
fecal
score
daili
record
frequenc
defec
studi
endpoint
form
fece
survey
question
includ
durat
diarrheal
sign
previou
histori
diarrhea
possibl
trigger
event
dietari
indiscret
intent
diet
chang
stress
owner
ask
indic
clinic
sign
includ
hematochezia
melena
tenesmu
chang
defec
frequenc
presenc
mucu
subject
water
content
fece
wateri
semiform
addit
data
collect
dog
includ
age
sex
breed
spay
neuter
statu
bodi
weight
blood
collect
enrol
dog
complet
blood
count
serum
biochemistri
fece
obtain
possibl
time
examin
fecal
flotat
commerci
pcr
gastrointestin
panel
canin
diarrhea
realpcr
panel
idexx
laboratori
westbrook
detect
campylobact
coli
campylobact
jejuni
canin
circoviru
canin
distemp
viru
cdv
canin
enter
coronaviru
cecov
canin
parvoviru
clostridium
difficil
toxin
ab
clostridium
perfringen
alpha
toxin
cpa
clostridium
perfringen
enterotoxin
cpe
clostridium
perfringen
netef
gene
cpnetef
cryptosporidium
spp
giardia
spp
salmonella
spp
clinician
permit
discret
administ
fluid
therapi
subcutan
intraven
fenbendazol
andor
maropit
order
maxim
clinician
client
enrol
treatment
examin
find
record
medic
record
dog
withdrawn
studi
due
owner
noncompli
treatment
administr
abnorm
note
postenrol
laboratori
pcr
test
support
diagnosi
uncompl
diarrhea
presenc
occasion
parasit
ova
fecal
sampl
dog
enrol
present
group
base
result
prestudi
power
analysi
group
size
like
produc
clinic
signific
reduct
day
time
normal
fece
use
mean
standard
deviat
previou
studi
vs
day
sd
day
alpha
beta
studi
unblind
investig
enrol
dog
perform
statist
analys
dog
assign
use
prestudi
random
schedul
obtain
random
sort
featur
commerci
softwar
program
excel
mac
version
microsoft
redmond
wa
receiv
one
three
treatment
includ
commerci
probiot
product
oral
metronidazol
placebo
attend
clinician
clinician
obtain
followup
owner
blind
treatment
administ
twice
daili
day
first
dose
administ
follow
initi
examin
irrespect
whether
patient
immedi
discharg
owner
care
hospit
probiot
vital
vet
vital
planet
palm
harbor
fl
provid
vegetablebas
capsul
label
guarante
billion
coloni
form
unit
cfu
measur
valu
billion
cfu
initi
studi
per
capsul
mixtur
follow
bacteri
strain
bifidobacterium
bifidum
bifidobacterium
longum
bifidobacterium
animali
bifidobacterium
infanti
lactobacillu
acidophilu
lactobacillu
plantarum
lactobacillu
casei
lactobacillu
brevi
lactobacillu
reuteri
lactobacillu
bulgaricu
probiot
capsul
contain
mg
blend
organ
acacia
gum
fructooligosaccharid
fo
metronidazol
powder
given
gelatin
capsul
accord
weightrang
administr
schedul
mg
administ
twice
daili
dog
kg
mg
dog
kg
mg
dog
kg
placebo
capsul
contain
sucros
equal
volum
probiot
metronidazol
capsul
capsul
visual
differ
prepar
licens
pharmacist
metronidazol
probiot
manufactur
probiot
placebo
dispens
vial
label
instruct
letter
group
assign
identifi
treatment
indic
owner
ask
monitor
dog
daili
follow
discharg
fecal
qualiti
report
worsen
emerg
servic
dog
hospit
base
owner
prefer
facilit
clinicianord
treatment
day
hospit
record
owner
provid
standard
discharg
instruct
feed
instruct
suggest
h
fast
follow
slow
reintroduct
food
subsequ
h
diarrhea
significantli
worsen
base
owner
report
increas
frequenc
worsen
fecal
score
increas
hematochezia
worsen
strain
owner
given
option
rescu
antibiot
treatment
day
treatment
period
studi
complet
day
diarrhea
resolv
tylosin
mgkg
po
twice
daili
day
client
ask
return
hospit
patient
condit
deterior
inform
would
charg
followup
medic
treatment
exampl
deterior
provid
owner
includ
lethargi
persist
vomit
melena
inappet
h
durat
concern
behavior
symptom
survey
sent
month
enrol
last
dog
determin
anoth
diarrhea
episod
occur
follow
studi
complet
probiot
potenc
test
manufactur
month
evalu
effect
storag
time
given
probiot
prepar
start
studi
period
test
perform
without
knowledg
studi
author
use
probiot
viabil
test
outsid
laboratori
data
assess
normal
andersondarl
analysi
parametr
group
data
compar
oneway
analysi
varianc
anova
nonparametr
data
kruskalw
statist
signific
establish
probabl
error
parametr
data
report
mean
standard
deviat
twoproport
ztest
perform
treatment
group
follow
observ
previou
histori
diarrhea
incit
caus
dietari
indiscret
stress
food
chang
vomit
hematochezia
fluid
therapi
maropit
administr
fenbendazol
administr
submiss
fecal
flotat
fecal
pcr
presenc
toxocara
cani
cpa
cpe
cpnetef
campylobact
coli
circoviru
signific
establish
use
bonferroni
correct
p
freemanhaltonfish
exact
probabl
test
perform
assess
differ
number
dog
treatment
group
diarrhea
month
poststudi
period
p
consid
signific
order
evalu
effect
treatment
well
possibl
confound
variabl
associ
time
requir
achiev
form
fece
backward
linear
regress
analysi
perform
follow
factor
consid
addit
treatment
group
age
bodi
weight
previou
histori
diarrhea
type
incit
caus
dietari
indiscret
stress
intent
food
chang
vomit
hematochezia
durat
clinic
sign
fluid
therapi
antiemet
administr
parasit
ova
presenc
c
perfringen
toxin
dichotom
variabl
dummi
code
entri
regress
model
variabl
remov
model
signific
p
variabl
includ
final
model
pvalu
iter
analys
perform
use
commerciallyavail
statist
softwar
minitab
express
minitab
state
colleg
pa
total
dog
enrol
studi
dog
success
complet
studi
divid
equal
among
three
treatment
group
three
dog
withdrawn
includ
final
analysi
due
either
signific
parasit
burden
n
metronidazol
group
failur
owner
give
assign
studi
treatment
n
one
probiot
placebo
group
group
comparison
summar
tabl
differ
detect
group
hematolog
biochem
analyt
p
dog
present
acut
diarrhea
achiev
accept
fecal
consist
day
receiv
probiot
day
metronidazol
day
placebo
p
mean
metronidazol
dose
mgkg
rang
mgkg
twice
daili
dog
treat
outpati
basi
hospit
time
h
advers
effect
treatment
group
note
dog
requir
rescu
treatment
tylosin
linear
regress
identifi
histori
previou
diarrhea
episod
episod
diarrhea
studi
n
number
given
n
positiven
sampl
submit
dog
suffici
sampl
analysi
result
statist
signific
ns
indic
signific
differ
pairwis
twoproport
ztest
assess
use
bonferroni
correct
p
consid
signific
cpa
c
perfringen
alpha
toxin
gene
cpe
clostridium
perfringen
enterotoxin
cpe
cpnetef
clostridium
perfringen
netef
gene
cpnetef
parasit
ova
dog
probiot
group
achiev
normal
fecal
consist
day
metronidazol
group
placebo
group
p
c
perfringen
alpha
toxin
gene
cpa
c
perfringen
enterotoxin
gene
cpe
c
perfringen
netef
gene
cpnetef
detect
number
patient
tabl
mean
gene
quantiti
copi
maximum
respect
valu
repres
n
n
n
respect
sampl
test
cutoff
suggest
test
provid
associ
diarrhea
dog
posit
cpe
cpnetef
also
posit
cpa
dog
posit
campylobact
jejuni
clostridium
difficil
toxin
ab
canin
distemp
viru
cdv
canin
enter
coronaviru
cecov
canin
parvoviru
cryptosporidium
spp
giardia
spp
salmonella
spp
forti
percent
owner
respond
request
longterm
followup
n
follow
studi
complet
diarrhea
report
followup
period
dog
inform
avail
tabl
n
substanti
deterior
probiot
product
time
report
manufactur
studi
author
studi
complet
billion
cfu
per
capsul
studi
initi
laboratori
analysi
manufactur
month
storag
time
half
dog
enrol
probiot
group
reveal
concentr
billion
cfu
detect
viabl
coloni
month
storag
howev
signific
differ
time
form
fece
first
half
day
second
half
day
dog
enrol
probiot
group
p
neither
probiot
product
metronidazol
achiev
statist
signific
improv
time
clinic
resolut
patient
enrol
studi
larg
standard
deviat
respons
treatment
consist
two
previou
studi
evalu
probiot
vs
placebo
acut
diarrhea
improv
previous
seen
probiot
identifi
studi
underpow
detect
differ
one
day
data
suggest
although
treatment
intervent
produc
statisticallysignific
differ
factor
frontier
veterinari
scienc
wwwfrontiersinorg
includ
previou
histori
diarrhea
dietari
indiscret
fluid
therapi
parasit
ova
may
confound
result
find
interpret
cautious
given
small
sampl
size
effect
previou
histori
diarrhea
may
suggest
inher
suscept
possibl
chronic
alter
microbiota
half
enrol
dog
present
studi
previou
histori
diarrhea
consist
anoth
investig
report
recurr
rate
acut
diarrhea
year
period
dietari
indiscret
scaveng
food
chang
known
risk
factor
diarrhea
previous
shown
affect
durat
sign
may
support
differ
mechan
stressor
kennelassoci
diarrhea
oppos
relat
dietari
intak
limit
present
studi
dog
screen
pancreat
use
serumbas
method
howev
dog
clinic
sign
suggest
pancreat
exclud
unlik
dietari
indiscret
influenc
sever
comorbid
undetect
addit
studi
whether
fluid
therapi
truli
impact
durat
diarrhea
would
necessari
gastrointestin
parasit
may
affect
time
resolut
even
though
dog
signific
ova
burden
exclud
studi
occur
despit
treatment
fenbendazol
previou
studi
suggest
endoparasit
influenc
occurr
gastrointestin
sign
howev
one
studi
identifi
toxocara
cani
parasit
four
posit
studi
case
diarrheal
dog
control
dog
anoth
studi
identifi
uncontrol
cohort
diarrheal
dog
reason
longer
durat
diarrhea
dog
parasit
present
studi
remain
unclear
could
due
parasit
caus
variabl
durat
diarrhea
impact
gastrointestin
mucosa
microbiom
conflict
data
exist
influenc
helminth
human
microbiom
host
immun
function
dog
low
parasit
ova
includ
studi
shorten
enrol
period
question
effect
produc
clinic
sign
acut
diarrhea
present
adult
dog
low
amount
howev
number
detect
ova
may
commensur
overal
parasit
burden
although
studi
result
unchang
dog
remov
data
set
futur
studi
probiot
metronidazol
exclud
dog
posit
parasit
detect
signific
pathogen
identifi
pcr
test
campylobact
coli
identifi
one
dog
may
incident
normal
dog
show
higher
cultur
campylobact
spp
compar
dog
diarrhea
canin
circoviru
identifi
two
dog
appear
independ
correl
sever
hemorrhag
diarrhea
dog
detect
giardia
spp
surpris
given
preval
describ
screen
studi
presenc
clostridium
spp
associ
toxin
group
expect
although
differ
detect
popul
compar
studi
cpa
cpe
known
occur
diarrheal
popul
healthi
dog
direct
detect
clostridium
perfringen
enterotoxin
identifi
vs
vs
vs
vs
dog
diarrhea
vs
control
four
studi
detect
cpa
gene
use
pcr
higher
studi
report
cpa
gene
detect
vs
control
one
studi
diarrheal
case
anoth
cpe
gene
copi
detect
enrol
dog
larg
consist
previou
report
dog
diarrhea
includ
hemorrhag
diarrhea
dog
without
gastrointestin
sign
four
percent
healthi
dog
report
cpa
cpe
cutoff
respect
causal
presenc
gene
diseas
durat
sever
establish
thirti
four
percent
fecal
sampl
test
present
investig
detect
cpnetef
gene
netf
encod
gene
previous
identifi
dog
diarrhea
dog
acut
hemorrhag
diarrhea
syndrom
clostridium
difficil
detect
pcr
studi
preval
larg
unknown
current
estim
diarrheal
dog
widespread
use
metronidazol
simpl
uncompl
diarrhea
diarrhea
absenc
system
sign
signific
hemorrhag
diarrhea
syndrom
without
c
perfringen
relat
toxin
support
data
small
studi
cohort
previou
report
compar
metronidazol
directli
placebo
present
studi
vs
day
would
clinic
insignific
even
adequ
number
show
statist
signific
minimum
dose
use
patient
consist
empir
dose
nonspecif
diarrhea
mgkg
twice
daili
lower
employ
studi
mgkg
twice
daili
neurolog
sign
appreci
higher
dose
mgkgd
associ
side
effect
previou
studi
use
metronidazol
control
option
treatment
evalu
probiot
metronidazol
addit
lack
proven
benefit
demonstr
mix
effect
healthi
canin
microbiom
antibiot
specif
amoxicillin
clavulan
acid
show
favor
effect
sever
canin
hemorrhag
diarrhea
contrast
probiot
acceler
faster
reduct
netf
encod
c
perfringen
although
dog
without
antibiot
treatment
also
resolv
result
studi
along
avail
data
suggest
metronidazol
use
except
case
specif
indic
treatment
giardia
spp
treatment
may
also
avail
limit
spectrum
infect
mean
time
resolut
day
shorter
dog
receiv
probiot
vs
placebo
statist
signific
establish
differ
exist
would
clinic
signific
dog
group
would
requir
therefor
studi
underpow
time
resolut
present
investig
similar
anoth
probiot
studi
clientown
acut
diarrheal
dog
report
day
resolut
diarrhea
patient
receiv
probiot
howev
previou
studi
placebo
group
took
significantli
longer
time
achiev
clinic
resolut
diarrhea
day
compar
current
studi
cohort
compris
younger
dog
resid
guidedog
train
facil
may
directli
compar
dog
enrol
present
trial
anoth
studi
demonstr
much
shorter
probiot
placebo
recoveri
period
vs
day
may
partial
due
longer
durat
clinic
sign
enrol
studi
day
vs
current
day
addit
dog
studi
exclud
attend
clinician
identifi
need
support
treatment
hospit
studi
shelter
dog
mix
like
compar
clientown
anim
given
differ
etiolog
time
present
clinic
improv
note
one
day
earlier
dog
administ
probiot
higher
cfu
sever
hemorrhag
diarrhea
vs
placebo
direct
compar
interpret
often
difficult
due
differ
strain
concentr
probiot
declin
probiot
cfu
may
due
lack
desicc
packet
airtight
seal
typic
commerci
product
includ
studi
due
standard
studyspecif
packag
watson
person
commun
differ
detect
first
second
half
dog
enrol
probiot
group
may
explain
variabl
respons
time
within
group
low
power
comparison
lack
efficaci
product
cfu
potenc
inform
unknown
research
studi
complet
provid
probiot
manufactur
author
therefor
correct
action
possibl
studi
impact
probiot
concentr
viabil
unclear
research
studi
speci
demonstr
benefit
dead
bacteria
cell
therefor
degrad
product
like
consid
equival
placebo
mismatch
commerci
probiot
claim
actual
potenc
appear
common
pet
supplement
market
case
like
due
inadvert
lack
normal
preserv
techniqu
use
commerci
version
product
past
studi
report
potenc
throughout
studi
durat
probiot
may
similarli
degrad
addit
optim
probiot
dose
establish
previou
studi
diarrhea
provid
billion
cfu
averages
dog
less
start
concentr
studi
futur
studi
monitor
probiot
viabil
establish
interv
studi
replenish
probiot
product
necessari
maintain
potenc
precautionari
measur
taken
ensur
prolong
viabil
label
claim
threshold
probiot
capsul
contain
potenti
prebiot
ferment
fiber
form
acacia
gum
fo
found
placebo
confound
evalu
probiot
strain
given
fiber
may
effect
bacteri
mass
composit
microbiom
acacia
gum
rapidli
ferment
solubl
fiber
smallest
dog
studi
fiber
would
contribut
one
percent
dri
matter
basi
total
estim
dietari
intak
consider
less
studi
dog
averag
size
estim
dri
matter
dietari
studi
dog
evalu
much
larger
amount
gum
use
probiot
product
similarli
fo
shown
caus
increas
bacteri
ferment
bacteri
shift
publish
investig
vari
inclus
rate
fiber
dm
higher
estim
administ
present
studi
futur
studi
may
better
evalu
independ
impact
probiot
prebiot
combin
inclus
similar
prebiot
placebo
studi
design
subject
number
limit
total
number
diarrhea
case
present
tertiari
referr
center
record
period
given
larg
case
volum
number
case
present
diarrhea
secondari
exclud
concurr
condit
foreign
bodi
toxic
etc
similarli
number
owner
declin
particip
track
given
larg
number
clinician
attend
case
therefor
select
bia
could
present
microbiom
metabolom
test
perform
treatment
might
elucid
cours
diseas
impact
potenti
pathogen
genera
like
clostridium
impact
previou
episod
diarrhea
might
also
explain
data
fecal
test
perform
possibl
dog
insuffici
sampl
retrospect
pcr
swab
colon
obtain
pcr
helminth
could
also
perform
clinician
discret
administ
fluid
maropit
empir
fenbendazol
potenti
confound
variabl
would
elimin
stringent
inclus
protocol
addit
dog
group
would
necessari
achiev
adequ
power
probiot
placebo
addit
number
would
potenti
permit
stratif
incit
caus
assess
differ
stressor
dietari
indiscretionrel
diarrhea
use
owner
report
fecal
consist
subject
potenti
imprecis
bia
use
dog
induc
coliti
would
provid
homogen
fail
reproduc
divers
diseas
seen
clinic
set
case
bia
may
also
occur
case
present
tertiari
referr
center
therefor
could
repres
refractori
sever
case
might
encount
primari
opinion
practic
owner
observ
limit
whole
treatment
day
therefor
could
occur
earlier
later
day
could
subject
recal
bia
collect
fecal
score
data
daili
basi
perform
would
provid
addit
data
albeit
expens
increas
effort
owner
suspect
reduc
owner
complianc
result
final
diet
uncontrol
treatment
period
inform
collect
regard
dietari
intervent
owner
consequ
amount
calor
nutrient
fiber
intak
could
influenc
fecal
microbiom
well
clinic
outcom
addit
studi
control
diet
possibl
limit
describ
herein
consist
multifactori
natur
diarrhea
treatment
well
inher
difficulti
assess
dog
return
owner
use
metronidazol
acut
diarrhea
appear
warrant
cohort
character
mild
moder
sign
hemorrhag
nonhemorrhag
acut
diarrhea
base
result
placebocontrol
trial
use
discourag
evidencebas
data
demonstr
differ
treatment
outcom
dog
acut
diarrhea
similarli
differ
detect
probiot
group
although
studi
underpow
larger
studi
perform
advers
effect
intervent
note
studi
perform
univers
florida
institut
anim
care
use
committe
iacuc
approv
studi
follow
guidelin
anim
use
accord
iacuc
client
own
dog
enrol
inform
consent
accord
declar
helsinki
use
form
approv
univers
florida
veterinari
hospit
research
review
committe
js
respons
concept
studi
data
interpret
supervis
data
collect
statist
analysi
draft
manuscript
cm
gm
respons
data
collect
analysi
enrolle
commun
review
relev
literatur
manuscript
revis
gb
respons
recruit
patient
manuscript
revis
clinic
trial
support
grant
vital
planet
llc
distribut
probiot
test
investig
